# US 2026/0083839 A1 · Methods of treating non-small cell lung cancer with anti-pd-1-antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0083839 A1
- Document ID: US20260083839A1
- Status: Published application
- Kind: A1
- Application number: 19/113,681
- Filed: 2023-09-22
- Published: 2026-03-26
- Earliest claimed: 2022-09-26
- Assignees: Tesaro, Inc.
- Applicants: Tesaro, Inc.
- Inventors: Martin HUBER; Niranjan YANAMANDRA; Allene DIAZ; Mary Lynne HEDLEY; Julie Ann KRUEGER; Timothy R. CROSSMAN; Hesham A. ABDULLAH
- Web page: https://patentgrep.com/patent/US20260083839A1

## CPC

- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 31/282: Platinum compounds
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 33/243: Platinum; Compounds thereof
- A61K 39/39541: {against normal tissues, cells}
- A61P 35/00: Antineoplastic agents
- C07K 16/2818: {against CD28 or CD152}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The disclosure provides a method of treating non-small cell lung cancer (NSCLC) in a patient previously treated with an immune checkpoint inhibitor by the administration of dostarlimab or a biosimilar thereof.

## Claims

### Claim 1

A method of treating non-small cell lung cancer (NSCLC) in a patient previously treated with a combination of (i) an anti-PD-1 antibody or an anti-PDL1 antibody that is not dostarlimab and (ii) one or more chemotherapeutic agents, the method comprising administering a therapeutically effective amount of dostarlimab to the patient, wherein the patient discontinued administration of the immune checkpoint inhibitor prior to beginning administration of dostarlimab.

### Claim 2

(canceled)

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The method of claim 1, wherein the anti-PD-1 antibody is selected from the group consisting of pembrolizumab, nivolumab, and cemiplimab.

### Claim 5 (depends on 4)

The method of claim 4, wherein the anti-PD-1 antibody is pembrolizumab.

### Claim 6

(canceled)

### Claim 7 (depends on 1)

The method of claim 1, wherein the anti-PD-L1 antibody is selected from the group consisting of atezolizumab, avelumab, and durvalumab.

### Claim at position 8

-27. (canceled)

### Claim 28 (depends on 1)

The method of claim 1, wherein the dostarlimab is administered at a dose of 500 mg.

### Claim 29 (depends on 28)

The method of claim 28, wherein the dostarlimab is administered through a 30 minute infusion intravenously Q3W.

### Claim 30 (depends on 29)

The method of claim 29, wherein the dostarlimab is administered at a dose of 1,000 mg beginning 3 weeks after dose 4.

### Claim 31 (depends on 30)

The method of claim 30, wherein the dostarlimab is administered every 6 weeks.

### Claim at position 13

-37. (canceled)

### Claim 38 (depends on 1)

The method of claim 1, wherein the NSCLC is metastatic NSCLC.

### Claim at position 15

-40. (canceled)

### Claim 41 (depends on 1)

The method of claim 1, wherein the patient has a PD-L1 tumor proportion score (TPS) of 50% or greater.

### Claim 42

A method of treating non-small cell lung cancer (NSCLC) in a patient previously treated with a combination of pembrolizumab, and one or more chemotherapeutic agents, the method comprising administering a therapeutically effective amount of dostarlimab, to the patient.

### Claim 43

(canceled)

### Claim 44 (depends on 42)

The method of claim 42, wherein the NSCLC is metastatic NSCLC.

### Claim at position 20

-75. (canceled)

### Claim 76 (depends on 1)

The method of claim 1, wherein said administration results in improved objective response rate (ORR) relative to administration of the immune checkpoint inhibitor that is not dostarlimab, and the one or more chemotherapeutic agents.

### Claim 77 (depends on 1)

The method of claim 1, wherein the method demonstrates non-inferiority to administration of the immune checkpoint inhibitor that is not dostarlimab, and the one or more chemotherapeutic agents.

### Claim 78 (depends on 77)

The method of claim 77, wherein non-inferiority is demonstrated using objective response rate (ORR).

### Claim at position 24

-90. (canceled)

### Claim 91

A method of treating non-small cell lung cancer (NSCLC) in a patient previously treated with chemotherapy and radiotherapy comprising administering dostarlimab or a biosimilar thereof 500 mg Q3W.

### Claim 92 (depends on 91)

The method of claim 91 wherein the dostarlimab or a biosimilar thereof is administered 1000 mg Q6W.

### Claim 93 (depends on 91)

The method of claim 91 wherein the patient has been previously treated with an anti-PD-L1 antagonist.

### Claim 94

(canceled)

### Claim 95

(canceled)
